My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Why Eli Lilly Stock Popped Today ↗

August 13, 2025

The GLP-1 weight loss wars have gone global.

Via The Motley Fool

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens ↗

August 13, 2025

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Via Benzinga

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗

August 13, 2025

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.

Via Benzinga

The 3 Things That Matter for Viking Therapeutics Now ↗

August 13, 2025

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Via The Motley Fool

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now ↗

August 12, 2025

Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.

Via Benzinga

Topics Lawsuit

UK Government, Eli Lilly Partner To Target Obesity Health Gaps ↗

August 12, 2025

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026.

Via Benzinga

Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock ↗

August 12, 2025

Investors have a tough choice between these two excellent companies.

Via The Motley Fool

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Value Investment with Undervalued Potential ↗

August 12, 2025

NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets.

Via Chartmill

Novo Nordisk Stock: Buy or Sell? ↗

August 12, 2025

News from a competitor is increasing enthusiasm for Novo Nordisk stock.

Via The Motley Fool

Is the Market Bullish or Bearish on Novo Nordisk? ↗

August 11, 2025

Via Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗

August 11, 2025

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to...

Via Benzinga

Topics Lawsuit

4 of the Most Undervalued Stocks in the Market Right Now ↗

August 11, 2025

They all offer great value right now.

Via The Motley Fool

2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade ↗

August 10, 2025

These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth.

Via The Motley Fool

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly ↗

August 09, 2025

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

Via MarketBeat

Topics Government World Trade

MarketBeat Week in Review – 08/04 - 08/08 ↗

August 09, 2025

Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales

Via MarketBeat

Topics ETFs Economy World Trade

Why Hims & Hers Stock Sank This Week ↗

August 09, 2025

The telehealth platform is growing quickly but is in the middle of a legal battle.

Via The Motley Fool

Topics Lawsuit

Why Novo Nordisk Stock Flew Higher on Friday ↗

August 08, 2025

It looked good next to a company that has been stealing its thunder lately.

Via The Motley Fool

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? ↗

August 08, 2025

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

Via MarketBeat

Novo Nordisk Stock Investors Need to Know This ↗

August 08, 2025

The company is using litigation to protect sales of its most popular treatments.

Via The Motley Fool

Novo Nordisk Is Down 70%: Is the Price Too Low To Ignore? ↗

August 08, 2025

Investors shouldn't expect a V-shaped recovery.

Via The Motley Fool

Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On? ↗

August 08, 2025

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Top Pick for Affordable Growth Investors ↗

August 08, 2025

NOVO-NORDISK A/S (NVO) offers affordable growth with strong revenue, earnings growth, and fair valuation, making it a top pick for balanced investors.

Via Chartmill

2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗

August 08, 2025

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Via The Motley Fool

Topics ETFs

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗

August 07, 2025

Via Stocktwits

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Via MarketMinute

Topics Economy

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗

August 07, 2025

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Via Benzinga

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗

August 07, 2025

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Via Investor's Business Daily

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk ↗

August 07, 2025

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance.

Via Benzinga

Topics Earnings

Why Novo Nordisk Stock Slipped Today ↗

August 06, 2025

The Danish pharmaceutical company is fighting a competitive war on several fronts.

Via The Motley Fool

Topics Lawsuit

Is It Time to Buy Biotech Stocks? ↗

August 06, 2025

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Via The Motley Fool

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.